Free Trial
→ White House to reset Social Security? (From Altimetry) (Ad)
NASDAQ:RENB

Renovaro 2/14/2024 Earnings Report

Renovaro logo
$0.32 +0.00 (+0.10%)
Closing price 04:00 PM Eastern
Extended Trading
$0.31 -0.01 (-1.90%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Renovaro EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Renovaro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Renovaro Announcement Details

Quarter
Date
2/14/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Renovaro Earnings Headlines

Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement
May 24, 2025 | nasdaq.com
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger
May 22, 2025 | insidermonkey.com
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
May 29, 2025 | Altimetry (Ad)
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
May 22, 2025 | globenewswire.com
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
May 22, 2025 | globenewswire.com
Renovaro partners with Amsterdam UMC on cancer diagnostics
May 15, 2025 | uk.investing.com
See More Renovaro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Renovaro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Renovaro and other key companies, straight to your email.

About Renovaro

Renovaro (NASDAQ:RENB), a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

View Renovaro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles